Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin C studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin CVitamin C (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 29% Improvement Relative Risk Mortality (b) 16% Vitamin C for COVID-19  Patel et al.  LATE TREATMENT Is late treatment with vitamin C beneficial for COVID-19? Retrospective 176 patients in the USA Lower mortality with vitamin C (not stat. sig., p=0.18) c19early.org Patel et al., Chest Infections, October 2020 Favors vitamin C Favors control

The significance of oral ascorbic acid in patients with COVID-19

Patel et al., Chest Infections, doi:10.1016/j.chest.2020.08.322
Oct 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin C for COVID-19
6th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.000000087 from 70 studies, recognized in 11 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Retrospective 176 hospitalized patients, 96 treated with oral vitamin C (from 500mg to 1500mg daily), showing lower mortality with treatment.
This is the 4th of 70 COVID-19 controlled studies for vitamin C, which collectively show efficacy with p=0.000000087 (1 in 11 million).
21 studies are RCTs, which show efficacy with p=0.0012.
risk of death, 29.5% lower, RR 0.71, p = 0.18, treatment 22 of 96 (22.9%), control 26 of 80 (32.5%), NNT 10.
risk of death, 15.6% lower, RR 0.84, p = 0.60, treatment 15 of 30 (50.0%), control 16 of 27 (59.3%), NNT 11, ICU patients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Patel et al., 1 Oct 2020, retrospective, USA, peer-reviewed, 8 authors.
This PaperVitamin CAll
THE SIGNIFICANCE OF ORAL ASCORBIC ACID IN PATIENTS WITH COVID-19
Manishkumar Patel, Gloria Hong, Bernadette Schmidt, Laith Al-Janabi, Radha Kishan Adusumilli, Jurgena Tusha, Padmini Giri, Sarwan Kumar
Chest, doi:10.1016/j.chest.2020.08.322
Our observational study showed even when ascorbic acid is administered in oral form as an adjunct to COVID-19 therapy, it is associated with a mortality benefit and improved extubation rate. DISCLOSURES: No relevant relationships by Radha Kishan Adusumilli, source¼Web Response No relevant relationships by Laith Al-janabi, source¼Web Response No relevant relationships by Padmini Giri, source¼Web Response No relevant relationships by Gloria Hong, source¼Web Response No relevant relationships by Sarwan Kumar, source¼Web Response No relevant relationships by Manishkumar Patel, source¼Web Response No relevant relationships by Bernadette Schmidt, source¼Web Response No relevant relationships by Jurgena Tusha, source¼Web Response
{ 'DOI': '10.1016/j.chest.2020.08.322', 'ISSN': ['0012-3692'], 'URL': 'http://dx.doi.org/10.1016/j.chest.2020.08.322', 'alternative-id': ['S0012369220325083'], 'author': [ {'affiliation': [], 'family': 'Patel', 'given': 'Manishkumar', 'sequence': 'first'}, {'affiliation': [], 'family': 'Hong', 'given': 'Gloria', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Schmidt', 'given': 'Bernadette', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Al-janabi', 'given': 'Laith', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Adusumilli', 'given': 'Radha Kishan', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Tusha', 'given': 'Jurgena', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Giri', 'given': 'Padmini', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Kumar', 'given': 'Sarwan', 'sequence': 'additional'}], 'container-title': 'Chest', 'container-title-short': 'Chest', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': { 'date-parts': [[2020, 10, 12]], 'date-time': '2020-10-12T10:45:50Z', 'timestamp': 1602499550000}, 'deposited': { 'date-parts': [[2020, 12, 2]], 'date-time': '2020-12-02T15:14:58Z', 'timestamp': 1606922098000}, 'indexed': {'date-parts': [[2024, 3, 19]], 'date-time': '2024-03-19T07:16:51Z', 'timestamp': 1710832611348}, 'is-referenced-by-count': 5, 'issue': '4', 'issued': {'date-parts': [[2020, 10]]}, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2020, 10]]}}, 'language': 'en', 'license': [ { 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2020, 10, 1]], 'date-time': '2020-10-01T00:00:00Z', 'timestamp': 1601510400000}}], 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0012369220325083?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0012369220325083?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'page': 'A325', 'prefix': '10.1016', 'published': {'date-parts': [[2020, 10]]}, 'published-print': {'date-parts': [[2020, 10]]}, 'publisher': 'Elsevier BV', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0012369220325083'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [ 'Cardiology and Cardiovascular Medicine', 'Critical Care and Intensive Care Medicine', 'Pulmonary and Respiratory Medicine'], 'subtitle': [], 'title': 'THE SIGNIFICANCE OF ORAL ASCORBIC ACID IN PATIENTS WITH COVID-19', 'type': 'journal-article', 'volume': '158'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit